GlassScriptPhysician profile
Amanda I Andrade
NPI 1750730461
$812.46
in general payments reported to CMS, 2019-2025
17 companies · $24.54 in 2025
The $24.54 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.73 · 2021: $488 · 2022: $32.35 · 2023: $121 · 2024: $86.96 · 2025: $24.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $178.38 | 2020-2022 | |
| Agile Therapeutics, INC. | $92.87 | 2021-2024 | Twirla |
| Next Science LLC | $90.60 | 2021 | |
| Organon LLC | $77.87 | 2021-2024 | Nexplanon |
| Medtronic, INC. | $44.75 | 2023 | |
| Evofem Biosciences, INC. | $43.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.07 | 2021 | |
| Merck Sharp & Dohme LLC | $34.70 | 2021 | |
| Exeltis, USA INC. | $34.66 | 2020-2021 | |
| Avion Pharmaceuticals | $33.91 | 2021 | |
| Aspira Women'S Health INC | $31.53 | 2024 | Ova1 |
| Myovant Sciences INC. | $24.95 | 2021 | |
| Sumitomo Pharma America, INC. | $24.54 | 2025 | Myfembree |
| Lupin INC. | $17.08 | 2021 | |
| Coopersurgical, INC. | $16.72 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $14.37 | 2024 | |
| Therapeuticsmd, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.